Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study

BACKGROUND: The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55–69. Knowing how the potential benefits and harms of screening vary by an individual’s risk of developing prostate cancer could infor...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:PLoS Med
Egile Nagusiak: Callender, Tom, Emberton, Mark, Morris, Steve, Eeles, Ros, Kote-Jarai, Zsofia, Pharoah, Paul D. P., Pashayan, Nora
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2019
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6924639/
https://ncbi.nlm.nih.gov/pubmed/31860675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1002998
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak